Japan Falls to Third-Largest Global Creditor as China Overtakes in 2025 
European EV Sales Surge in April 2026 as Tesla and Chinese Automakers Gain Ground 
ASX Shares Plunge as Rising Tech Upgrade Costs Shake Investor Confidence 
SK Hynix Joins $1 Trillion Club as AI Chip Demand Fuels Stock Surge 
SpaceX Starship V3 Test Flight Boosts IPO Momentum Ahead of Historic Market Debut 
SpaceX IPO Hype Raises Questions as Many Major Stock Debuts Underperform Market 
Xiaomi Shares Drop After Weak Q1 Earnings Amid Rising Smartphone Costs 
Asian Stocks Slip as U.S.-Iran Tensions Weigh on Markets; South Korea’s KOSPI Hits Record High 
Australia Inflation Cools in April as Fuel Prices Ease, But Core CPI Remains Sticky 
SQM Q1 Profit More Than Doubles as Lithium Prices Surge 
Croatia Weighs Ante Zigman for Central Bank Governor Role in Key ECB Transition 
Sri Lanka Central Bank Surprises Markets With 100 Basis Point Rate Hike Amid Inflation and Currency Pressure 
Samsung Workers Approve Wage Deal, Avoiding Major Strike and Boosting Chip Supply Confidence 
Texas Sues Meta Over WhatsApp Encryption Claims 
Puerto Rico Economic Development Chief Resigns Amid Government Shake-Up 
Samsung Union Dispute Escalates Over Semiconductor Bonus Vote 
CTOC Goes Live on Bitget Wallet Trading, Expanding Global Access to AI-Powered Healthcare Data Ecosystem 
Lotte Biologics has inked a memorandum of understanding (MOU) with Roche Diagnostics to bolster its Contract Development and Manufacturing Organization (CDMO) capabilities. This collaboration signifies major diagnostics, hardware, and automation advancements for Lotte's upcoming Korean production plants.
On Wednesday, Aug. 9, Lotte Biologics said it will work with Roche Diagnostics to improve the productivity and quality of its productions. The company said they would also team up to establish hardware and automation systems for Lotte's upcoming production plants in Korea, as per Korea Joongang Daily.
The MOU was signed at Roche Diagnostics CustomBiotech Center in Penzberg, Germany. Lotte Biologics' chief executive officer, Richard Lee; Roche Diagnostics CustomBiotech's vice president, Rainer Mueller; and Roche Diagnostics Korea's general manager, Kit Tang, were all present at the signing ceremony.
With the deal in place, Lotte Biologics aims to amplify its credibility with future global clients. The agreement will also serve as the forefront to underpin and shore up Roche Diagnostics' supply network in the Asian market. This will also give better treatment access to patients around the world.
"Through this MOU, we plan to enhance the production process capabilities of our Korean Mega Plant in collaboration with Roche Diagnostics," Lotte Biologics chief Richard Lee said in a press release. "Through synergy with Roche Diagnostics, an industry leader in the in vitro diagnostic field, LOTTE hopes to improve the efficiency of its operations at the forthcoming Korean Mega Plant, simultaneously augmenting the quality of our manufacturing and fulfilling customer needs."
Finally, Business Korea reported that Lotte Biologics and Roche Diagnostics will cooperate on various business fronts, including installing automation systems at the former's Mega Plants that will be built in Korea. The latter will also provide technical consulting and equipment support for the facilities.
Photo by: Lotte Biologics Newsroom
